Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension

Phase 3 Completed 2694 enrolled Novartis Pharmaceuticals

RandomizedFactorialTriple-blindTreatment

Summary

Evaluate the efficacy (blood pressure lowering effect) and safety of aliskiren alone and in combination with amlodipine in patients with essential hypertension.

Timeline

Start: 2008-09
Primary completion: 2009-05
Completion: 2009-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Aliskiren	Small molecule	150 mg	Oral
Subject	Aliskiren	Small molecule	300 mg	Oral
Subject	Amlodipine	Other / unclassified	5 mg	Oral
Subject	Amlodipine	Other / unclassified	10 mg	Oral

Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension

Summary

Timeline

Drugs

Indications